应用奥扎格雷钠治疗肺心病急性加重期高凝状态的临床分析(1)
【摘要】 目的 研究奥扎格雷钠应用于肺源性心脏病(肺心病)急性加重期高凝状态的治疗效果。方法 86例肺心病急性加重期患者， 将其随机分为对照组与观察组， 各43例。对照组实施常规治疗， 观察组在对照组基础上给予奥扎格雷钠治疗。观察两组患者治疗后的临床效果、凝血因子水平以及血气分析情况。结果 观察组治疗后的总有效率为93.02%， 高于对照组的72.09%， 差异有统计学意义(P<0.05)。观察组的6-酮-前列腺素F1α水平为(34.52±6.78)ng/L， 血栓素B2水平为(150.62±20.15)ng/L， 氧分压为(9.89±0.76)kPa， 二氧化碳分压为(6.37±1.26)kPa， 均优于对照组的(24.14±7.06)ng/L、(178.39± 25.24)ng/L、(8.31±0.65)kPa和(7.62±1.09)kPa， 差异有统计学意义(P<0.05)。结论 奥扎格雷钠应用于肺心病急性加重期的治疗中， 能够明显控制疾病发展， 改善高凝状态， 值得临床推广。
【关键词】 奥扎格雷钠；肺源性心脏病；急性加重期；高凝状态
DOI：10.14163/j.cnki.11-5547/r.2016.33.051
Clinical analysis of sodium ozagrel applied in treating hypercoagulable state in acute exacerbation of pulmonary heart disease WANG Hong. Department of Respiratory Medicine， Liaoning Donggang City Central Hospital， Donggang 118300， China
【Abstract】 Objective To research curative effect by sodium ozagrel applied in treating hypercoagulable state in acute exacerbation of pulmonary heart disease. Methods A total of 86 patients with acute exacerbation of pulmonary heart disease were randomly divided into control group and observation group， with 43 cases in each group. The control group received conventional therapy， and the observation group received additional sodium ozagrel for treatment. Observation was made on clinical effect， blood coagulation factor level and blood gas analysis in both groups after treatment. Results The observation group had higher total effective rate as 93.02% than 72.09% in the control group， and the difference had statistical significance (P<0.05). The observation group had 6-keto prostaglandin F1α as (34.52±6.78) ng/L， thromboxane B2 as (150.62±20.15) ng/L， partial pressure of oxygen as (9.89±0.76) kPa， partial pressure of carbon dioxide as (6.37±1.26) kPa， which were all better than (24.14±7.06) ng/L， (178.39±25.24) ng/L， (8.31±0.65) kPa and (7.62±1.09) kPa in the control group， and their difference had statistical significance (P<0.05). Conclusion Implement of sodium ozagrel in treating acute exacerbation of pulmonary heart disease can remarkably suppress disease development and improve hypercoagulable state. This method is worth clinical promotion.
【Key words】 Sodium ozagrel； Pulmonary heart disease； Acute exacerbation； Hypercoagulable state
肺心病是一種晚期疾病， 患者全身脏器会出现不可逆的功能性障碍， 血液会出现高凝现象， 引起血栓， 极易导致死亡[1-3]， 如何进行有效的疾病预防、治疗是急需解决的问题。本文为探讨奥扎格雷钠应用于肺心病急性加重期患者的治疗中对其血液高凝状态的影响， 选取了86例患者作为研究对象， 具体内容如下。
1 资料与方法
1. 1 一般资料 选取2015年2月～2016年5月于本院就诊的86例肺心病急性加重期患者进行研究， 将其随机分为对照组和观察组， 每组43例。所有患者及家属均获知情权， 且同意加入此次研究。对照组患者中男24例、女19例， 年龄最大75岁， 最小42岁， 平均年龄(63.49±7.28)岁。观察组患者中男23例、女20例， 年龄最大74岁， 最小43岁， 平均年龄(63.21±7.07)岁。两组患者一般资料比较差异无统计学意义(P>0.05)， 具有可比性。, http://www.100md.com(王红)
【关键词】 奥扎格雷钠；肺源性心脏病；急性加重期；高凝状态
DOI：10.14163/j.cnki.11-5547/r.2016.33.051
Clinical analysis of sodium ozagrel applied in treating hypercoagulable state in acute exacerbation of pulmonary heart disease WANG Hong. Department of Respiratory Medicine， Liaoning Donggang City Central Hospital， Donggang 118300， China
【Abstract】 Objective To research curative effect by sodium ozagrel applied in treating hypercoagulable state in acute exacerbation of pulmonary heart disease. Methods A total of 86 patients with acute exacerbation of pulmonary heart disease were randomly divided into control group and observation group， with 43 cases in each group. The control group received conventional therapy， and the observation group received additional sodium ozagrel for treatment. Observation was made on clinical effect， blood coagulation factor level and blood gas analysis in both groups after treatment. Results The observation group had higher total effective rate as 93.02% than 72.09% in the control group， and the difference had statistical significance (P<0.05). The observation group had 6-keto prostaglandin F1α as (34.52±6.78) ng/L， thromboxane B2 as (150.62±20.15) ng/L， partial pressure of oxygen as (9.89±0.76) kPa， partial pressure of carbon dioxide as (6.37±1.26) kPa， which were all better than (24.14±7.06) ng/L， (178.39±25.24) ng/L， (8.31±0.65) kPa and (7.62±1.09) kPa in the control group， and their difference had statistical significance (P<0.05). Conclusion Implement of sodium ozagrel in treating acute exacerbation of pulmonary heart disease can remarkably suppress disease development and improve hypercoagulable state. This method is worth clinical promotion.
【Key words】 Sodium ozagrel； Pulmonary heart disease； Acute exacerbation； Hypercoagulable state
肺心病是一種晚期疾病， 患者全身脏器会出现不可逆的功能性障碍， 血液会出现高凝现象， 引起血栓， 极易导致死亡[1-3]， 如何进行有效的疾病预防、治疗是急需解决的问题。本文为探讨奥扎格雷钠应用于肺心病急性加重期患者的治疗中对其血液高凝状态的影响， 选取了86例患者作为研究对象， 具体内容如下。
1 资料与方法
1. 1 一般资料 选取2015年2月～2016年5月于本院就诊的86例肺心病急性加重期患者进行研究， 将其随机分为对照组和观察组， 每组43例。所有患者及家属均获知情权， 且同意加入此次研究。对照组患者中男24例、女19例， 年龄最大75岁， 最小42岁， 平均年龄(63.49±7.28)岁。观察组患者中男23例、女20例， 年龄最大74岁， 最小43岁， 平均年龄(63.21±7.07)岁。两组患者一般资料比较差异无统计学意义(P>0.05)， 具有可比性。, http://www.100md.com(王红)